Apyx Medical Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $177.3M
- Price
- $4.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.24%
- Volume
- 40.6K
Quote data as of 6:11 AM ET
About
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Quick stats
Shares outstanding42.1M
Computed float32.3M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000719135
Websitehttps://www.apyxmedical.com
AI Summary
AI-generated2mo agomajorbullishclinical trialApyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
Apyx Medical Corporation announced the publication of a new retrospective study in Plastic and Reconstructive Surgery - Global Open, evaluating the clinical benefit of Renuvion when used in combination with liposuction.
The study found that patients treated with Renuvion reported statistically higher satisfaction with reduced appearance of excess skin (Body-Q score 87.8 vs. 73.8; p=0.03) and abdominal appearance (68.8 vs. 45.0; p=0.039).
The rate of patients requiring abdominoplasty was more than 50% lower in the Renuvion group (30.0% vs. 67.1%), and revision rates were significantly lower (12.0% vs. 37.5%; p=0.038), while complication rates remained similar (2.5% vs. 2.7%).
CEO Charlie Goodwin stated that the study adds to the growing body of clinical evidence supporting the use of Renuvion in aesthetic body contouring, underscoring its value to surgeons and patients.